Arbutus Biopharma (ABUS) EBITDA (2013 - 2026)

Arbutus Biopharma has disclosed EBITDA across 14 years of filings, most recently posting $169.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at $169.6 million, up 790.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.7 million (up 310.42% YoY), and the FY2025 annual result was -$33.5 million, up 51.94% from the prior year.
• EBITDA came in at $169.6 million for Q1 2026 at Arbutus Biopharma, up from -$3.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $169.6 million in Q1 2026 to a low of -$24.6 million in Q1 2025.
• The 5-year median for EBITDA is -$16.9 million (2023), against an average of -$4.5 million.
• Across the five-year window, EBITDA tumbled 37.77% in 2025 and jumped 790.63% in 2026, its largest moves.
• Arbutus Biopharma's EBITDA stood at -$21.4 million in 2022, then increased by 11.99% to -$18.8 million in 2023, then surged by 33.27% to -$12.6 million in 2024, then soared by 70.38% to -$3.7 million in 2025, then soared by 4652.97% to $169.6 million in 2026.
• The last three EBITDA figures came in at $169.6 million (Q1 2026), -$3.7 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.